This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment


Abbatecola, Angela M., Lattanzio, Fabrizia, Molinari, Anna M., Cioffi, Michele, Mansi, Luigi, Rambaldi, Pierfrancesco, DiCioccio, Luigi, Cacciapuoti, Federico, Canonico, Raffaele, Paolisso, Giuseppe


Diabetes Care, Volume: 33, No.: 8, Pages.: 1706-1711

Year of Publication



Objective: Studies have suggested that insulin resistance plays a role in cognitive impairment in individuals with type 2 diabetes. We aimed to determine whether an improvement in insulin resistance could explain cognitive performance variations over 36 weeks in older individuals with mild cognitive impairment (MCI) and type 2 diabetes.; Research Design and Methods: A total of 97 older individuals (mean +/- SD age 76 +/- 6 years) who had recently (<2 months) started an antidiabetes treatment of metformin (500 mg twice a day) (n = 30) or metformin (500 mg/day)+rosiglitazone (4 mg/day) (n = 32) or diet (n = 35) volunteered. The neuropsychological test battery consisted of the Mini-Mental State Examination (MMSE), Rey Verbal Auditory Learning Test (RAVLT) total recall, and Trail Making Tests (TMT-A and TMT-B) performed at baseline and every 12 weeks for 36 weeks along with clinical testing.; Results: At baseline, no significant differences were found between groups in clinical or neuropsychological parameters. Mean +/- SD values in the entire population were as follows: A1C 7.5 +/- 0.5%, fasting plasma glucose (FPG) 8.6 +/- 1.3 mmol/l, fasting plasma insulin (FPI) 148 +/- 74 pmol/l, MMSE 24.9 +/- 2.4, TMT-A 61.6 +/- 42.0, TMT-B 162.8 +/- 78.7, the difference between TMT-B and TMT-A [DIFFBA] 101.2 +/- 58.1, and RAVLT 24.3 +/- 2.1. At follow-up, ANOVA models tested changes in metabolic control parameters (FPI, FPG, and A1C). Such parameters improved in the metformin and metformin/rosiglitazone groups (P(trend) < 0.05 in both groups). ANCOVA repeated models showed that results for the metformin/rosiglitazone group remained stable for all neuropsychological tests, and results for the diet group remained stable for the MMSE and TMT-A and declined for the TMT-B (P(trend) = 0.024), executive efficiency (DIFFBA) (P(trend) = 0.026), and RAVLT memory test (P(trend) = 0.011). Results for the metformin group remained stable for the MMSE and TMTs but declined for the RAVLT (P(trend) = 0.011). With use of linear mixed-effects models, the interaction term, FPI x time, correlated with cognitive stability on the RAVLT in the metformin/rosiglitazone group (beta = -1.899; P = 0.009).; Conclusions: Rosiglitazone may protect against cognitive decline in older individuals with type 2 diabetes and MCI.;

Bibtex Citation

@article{Abbatecola_2010, doi = {10.2337/dc09-2030}, url = {}, year = 2010, month = {apr}, publisher = {American Diabetes Association}, volume = {33}, number = {8}, pages = {1706--1711}, author = {A. M. Abbatecola and F. Lattanzio and A. M. Molinari and M. Cioffi and L. Mansi and P. Rambaldi and L. DiCioccio and F. Cacciapuoti and R. Canonico and G. Paolisso}, title = {Rosiglitazone and Cognitive Stability in Older Individuals With Type 2 Diabetes and Mild Cognitive Impairment}, journal = {Diabetes Care} }


aged, aged, 80 and over, and, cognition, diabetes, diabetes mellitus type 2, drug effects, drug therapy, female, humans, hypoglycemic agents, male, metformin, physiopathology, rosiglitazone, therapeutic use, thiazolidinediones

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions, Risk Factor Modification

Risk Factor Modifications

At risk population

Pharmaceutical Interventions